Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Bailey DB, Raspa M, Bishop E, Mitra D, Wheeler A, Sacco P. Health and economic consequences of Fragile X syndrome for caregivers. J Dev Behav Pediatr. 2012 Nov 1;33(9):705-12.